Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

What Does the Forecast Indicate for the Anti-Hypertensive Drugs Market From 2025 to 2029?

The market size for peripheral vasodilator drugs has seen substantial growth in recent years. It is expected to enhance from $6.27 billion in 2024 to $6.61 billion in 2025, projecting a compound annual growth rate (CAGR) of 5.3%. Factors contributing to this hike in the historic period include a shift toward less invasive surgical methods, an increased demand for minimally invasive heart devices, continuous education and training programs for healthcare professionals, increased healthcare spending, and a rising patient inclination for non-surgical or minimally invasive procedures.

The market for peripheral vasodilator drugs is poised for robust expansion in the upcoming years, projected to reach a valuation of “$8.18 billion by 2029, with a compound annual growth rate (CAGR) of 5.5%.” Factors like the aging population, increased consciousness about cardiac health, adoption of screening programs, advantageous reimbursement schemes for structural heart treatments, and prompt regulatory green light for novel structural heart instruments are fueling this growth. The forecast period would also see a rise in trends such as enhanced collaboration, real-world evidence, gene therapy, prophylactic interventions, and value-based medical care.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=16508&type=smp

What Elements Are Contributing To Growth In The Anti-Hypertensive Drugs Market?

The expansion of the anti-hypertensive drug market is largely fuelled by a sedentary lifestyle. Factors such as excessive consumption of fast food, a deficiency in proper and balanced nutrition, and an insufficient amount of sleep owing to erratic work timings, have all led to a surge in hypertension. Hypertension is a direct cause of around 45% of heart disease-related deaths and 51% of stroke-related deaths. After hypertension is diagnosed in a patient, it becomes essential for them to consume medication based on the degree of their condition. For instance, data released by the National Health Service, a government department in England, in May 2023, revealed that hypertension prevalence increases with age. It starts at 9% in adults between 16 to 44, and escalates to 60% among those aged 65 and above. Such trends ensure an ongoing demand for these drugs, making it a significant driver for market growth.

The peripheral vasodilator drugs market covered in this report is segmented –

1) By Drug Type: Calcium Channel Blockers, Direct-Acting Vasodilators, Alpha-Adrenergic Blockers, Potassium Channel Activators, Nitrates, Other Types

2) By Indication: Hypertension, Angina, Heart Failure, Other Indications

3) By Application: Hospital, Retail Pharmacies, Other Applications

Subsegments:

1) By Calcium Channel Blockers: Dihydropyridines, Non-Dihydropyridines

2) By Direct-Acting Vasodilators: Hydralazine, Minoxidil, Nitroprusside

3) By Alpha-Adrenergic Blockers: Prazosin, Doxazosin, Terazosin

4) By Potassium Channel Activators: Nicorandil, Diazoxide

5) By Nitrates: Nitroglycerin, Isosorbide Dinitrate, Isosorbide Mononitrate

6) By Other Types: Phosphodiesterase Inhibitors, Endothelin Receptor Antagonists

Which Emerging Trends And Strategic Shifts Are Shaping The Anti-Hypertensive Drugs Market?

Main players in the peripheral vasodilator drugs market are concentrating on the enhancement of drug development through triple-drug combination therapies, aiming to improve treatment results and boost their market position in cardiovascular therapeutics. The triple-drug combination therapy is an antihypertensive fixed-dose combination (FDC) designed for patients who failed to achieve sufficient blood pressure control through dual-drug therapies or couldn’t cope with diuretic-based combinations. For example, in August 2023, Ajanta Pharma Limited, a pharmaceutical firm based in India with a special focus on cardiology, launched Met XL AMT, an innovative triple-drug combination meant to manage hypertension among the Indian population. This new drug is a FDC of three antihypertensive agents: Telmisartan, Amlodipine, and Metoprolol, which collectively relax the blood vessels to reduce blood pressure, a function distinctive to peripheral vasodilators. The DCGI has specifically approved the drug for managing uncontrolled hypertension while treating stable coronary artery disease, positioning it as the world’s first FDC of metoprolol succinate (extended-release) 50 mg, amlodipine 5 mg, and telmisartan 40 mg.

Who Are The Key Contributors To Growth In The Anti-Hypertensive Drugs Market?

Major companies operating in the peripheral vasodilator drugs market are Pfizer Inc., Bayer AG, Sanofi S.A., Thermo Fisher Scientific Inc., AstraZeneca PLC, Abbott Laboratories, Novartis AG, GSK plc, Takeda Pharmaceutical Company, Gilead Sciences Inc, Amgen Inc, Boehringer Ingelheim International GmbH, Merck & Co, Viatris Inc., Baxter, Teva Pharmaceutical Industries, Astellas Pharma, Daiichi Sankyo Company, Limited, Sun Pharmaceutical Industries, Mitsubishi Tanabe Pharma, Cipla Limited, Hikma Pharmaceuticals, Lupin Pharmaceuticals, Glenmark Pharmaceuticals Ltd, Torrent Pharmaceuticals, Ipca Laboratories, Alembic Pharmaceuticals

https://www.thebusinessresearchcompany.com/report/peripheral-vasodilator-drugs-global-market-report

Which Region Is Projected To Lead The Anti-Hypertensive Drugs Market By 2025?

North America was the largest region in the peripheral vasodilator drugs market in 2024. The regions covered in the peripheral vasodilator drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=16508&type=smp

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model